Can hyoscine butylbromide be used for abdominal pain in children, and what is the recommended dose and safety profile?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 21, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can Hyoscine Butylbromide Be Given for Abdominal Pain in Children?

Hyoscine butylbromide can be used for nonspecific colicky abdominal pain in children aged 8-17 years, but it is not superior to acetaminophen and should be considered as an alternative rather than first-line option. 1

Evidence-Based Recommendation

The American Academy of Pediatrics recommends oral ibuprofen (5-10 mg/kg every 6-8 hours) or acetaminophen (10-15 mg/kg every 4-6 hours) as first-line treatment for mild to moderate abdominal pain in children if no contraindications exist. 2, 3 Hyoscine butylbromide may be considered when functional abdominal pain is provoked by meals, though supporting evidence in children remains limited. 2

Pediatric Evidence for Hyoscine Butylbromide

A 2020 randomized controlled trial in children aged 8-17 years with nonspecific colicky abdominal pain demonstrated that:

  • Hyoscine butylbromide 10 mg orally was not superior to acetaminophen 15 mg/kg (adjusted difference 1 mm on visual analogue scale, 95% CI -7 to 7). 1
  • Both agents produced clinically important pain reduction, with mean pain scores of 29 mm (hyoscine) versus 30 mm (acetaminophen) at 80 minutes. 1
  • Both medications were safe and well-tolerated with no serious adverse effects observed. 1
  • Adverse effects occurred in 27.6% with hyoscine versus 24.3% with acetaminophen (p = 0.5). 1

Dosing for Children

Based on the pediatric trial, the appropriate dose is 10 mg orally for children aged 8-17 years presenting with nonspecific colicky abdominal pain. 1 This is lower than adult dosing (20-100 mg/day). 4

When to Consider Hyoscine Butylbromide

Hyoscine butylbromide may be considered as an alternative antispasmodic agent when functional abdominal pain is provoked by meals, particularly when cramping or spasm-like pain is the predominant feature. 2 The drug works by blocking muscarinic receptors on gastrointestinal smooth muscle, producing a local spasmolytic effect. 5

Safety Profile

Hyoscine butylbromide has favorable safety characteristics in children:

  • Minimal systemic absorption (bioavailability <1%) means it acts locally in the intestine without significant central nervous system effects. 5
  • It does not cross the blood-brain barrier due to its quaternary ammonium structure. 6, 5
  • The drug has been used safely for over 60 years with few reported adverse events. 5, 7

Critical Limitations and Caveats

Do not withhold pain medication while awaiting diagnosis - this outdated practice impairs examination without improving diagnostic accuracy. 2, 3 Pain relief should be provided immediately upon presentation. 2

Hyoscine butylbromide should not replace standard first-line analgesics (ibuprofen or acetaminophen) in children, as it offers no superiority and has less pediatric evidence. 1, 2

Avoid in children with contraindications to anticholinergics, including narrow-angle glaucoma, myasthenia gravis, or megacolon. 5

Practical Algorithm for Use

  1. First-line: Administer oral ibuprofen (5-10 mg/kg) or acetaminophen (10-15 mg/kg) for mild-moderate abdominal pain. 2, 3

  2. Consider hyoscine butylbromide 10 mg orally as an alternative if:

    • Pain is specifically colicky/cramping in nature 1
    • Pain is provoked by meals 2
    • Standard analgesics are contraindicated or ineffective
  3. Escalate to IV opioids (morphine) for severe pain unresponsive to oral agents. 2, 3

Comparison to Adult Use

In adults, hyoscine butylbromide is commonly used as a gastrointestinal antispasmodic, though it is poorly absorbed orally and intramuscular preparations may be more effective. 6 For diagnostic imaging in adults, hyoscine butylbromide is the spasmolytic agent of choice to improve bowel distension during MR enterography. 6

References

Research

Hyoscine butylbromide versus acetaminophen for nonspecific colicky abdominal pain in children: a randomized controlled trial.

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2020

Guideline

Management of Abdominal Pain in Pediatric Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Management of Mesogastric Abdominal Pain in Children

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Related Questions

Is Buscopan (hyoscine butylbromide) indicated for symptom management in pancreatic cancer?
What is the preferred first-line option for managing abdominal pain in an adult patient with acute, non-bloody, and non-febrile diarrhea, between AINEs (Nonsteroidal Anti-Inflammatory Drugs) and hyoscine?
What is the recommended antispasmodic medication (antispasmodic) and dosage for managing abdominal cramps and spasms?
What is the recommended dosage of Buscopan (hyoscine butylbromide) for managing abdominal cramps or irritable bowel syndrome?
What are the recommended dosing regimens for butylscopolamine (hyoscine butylbromide) in adults and children, including maximum daily dose and routes of administration?
How can I determine whether a patient with prior positive Epstein‑Barr nuclear antigen IgG has a new Epstein‑Barr virus infection?
Is hyoscine (scopolamine) appropriate for use in pediatric patients, and what are the age restrictions and dosing guidelines for motion‑sickness prophylaxis, abdominal cramping, and pre‑operative sedation?
What laboratory studies should be obtained to evaluate a suspected sickle‑cell disease flare (vaso‑occlusive crisis or acute chest syndrome)?
If the laboratory only performs EBV (Epstein‑Barr virus) VCA‑IgM, VCA‑IgG, and EA‑IgG testing when the EBNA‑IgG (Epstein‑Barr nuclear antigen immunoglobulin G) screen is negative, how can I evaluate a possible new EBV infection in a patient who already has positive EBNA‑IgG from past exposure?
How should a patient with a BMI of 32 kg/m² be managed?
In a 17‑year‑old patient taking oxcarbazepine (Trileptal) 750 mg BID, buspirone (Buspar) 5 mg TID, topiramate (Topamax) 50 mg q12h, duloxetine (Cymbalta) 60 mg daily, and chlorpromazine (Thorazine) 75 mg TID, are there safety concerns with this medication regimen?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.